Terms: = Cervical cancer AND PTEN, MMAC1, 5728, MGC11227, PTEN1, MHAM, P60484, BZS, ENSG00000171862
197 results:
1. Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix.
Bellone S; Jeong K; Halle MK; Krakstad C; McNamara B; Greenman M; Mutlu L; Demirkiran C; Hartwich TMP; Yang-Hartwich Y; Zipponi M; Buza N; Hui P; Raspagliesi F; Lopez S; Paolini B; Milione M; Perrone E; Scambia G; Altwerger G; Ravaggi A; Bignotti E; Huang GS; Andikyan V; Clark M; Ratner E; Azodi M; Schwartz PE; Quick CM; Angioli R; Terranova C; Zaidi S; Nandi S; Alexandrov LB; Siegel ER; Choi J; Schlessinger J; Santin AD
Proc Natl Acad Sci U S A; 2024 Apr; 121(17):e2321898121. PubMed ID: 38625939
[TBL] [Abstract] [Full Text] [Related]
2. Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies.
Subbiah V; Coleman N; Piha-Paul SA; Tsimberidou AM; Janku F; Rodon J; Pant S; Dumbrava EEI; Fu S; Hong DS; Zhang S; Sun M; Jiang Y; Roszik J; Song J; Yuan Y; Meric-Bernstam F; Naing A
Cancer Res Commun; 2024 Feb; 4(2):378-387. PubMed ID: 38126764
[TBL] [Abstract] [Full Text] [Related]
3. Invasive stratified mucin-producing carcinoma (ISMC) of the cervix: a clinicopathological and molecular analysis of 59 cases with special emphasis on histogenesis and potential therapeutic targets.
Yao Y; Wang Y; Ye L; Lu B; Lu W
Histopathology; 2024 Jan; 84(2):315-324. PubMed ID: 37735961
[TBL] [Abstract] [Full Text] [Related]
4. Knockdown of miR-24 Suppressed the Tumor Growth of cervical Carcinoma Through Regulating pten/PI3K/AKT Signaling Pathway.
He H; Lin C; Lu Y; Wu H
Biochem Genet; 2024 Apr; 62(2):1277-1290. PubMed ID: 37589947
[TBL] [Abstract] [Full Text] [Related]
5. Clinical availability and characteristics of multigene panel testing for recurrent/advanced gynecologic cancer.
Kitazawa S; Chiyoda T; Nakamura K; Sakai K; Yoshihama T; Nishio H; Kobayashi Y; Iwata T; Banno K; Yamagami W; Nishihara H; Aoki D
Int J Clin Oncol; 2023 Nov; 28(11):1554-1562. PubMed ID: 37574505
[TBL] [Abstract] [Full Text] [Related]
6. Cytotoxic activity of quinolinequinones in cancer: In vitro studies, molecular docking, and ADME/PK profiling.
Jannuzzi AT; Yilmaz Goler AM; Shilkar D; Mondal S; Basavanakatti VN; Yıldırım H; Yıldız M; Çelik Onar H; Bayrak N; Jayaprakash V; TuYuN AF
Chem Biol Drug Des; 2023 Nov; 102(5):1133-1154. PubMed ID: 37537000
[TBL] [Abstract] [Full Text] [Related]
7. ELK4 Promotes Cell Cycle Progression and Stem Cell-like Characteristics in HPV-associated cervical cancer by Regulating the FBXO22/pten Axis.
Gao F; Wang C; Bai X; Ji J; Huang X
Balkan Med J; 2023 Oct; 40(6):409-414. PubMed ID: 37519006
[TBL] [Abstract] [Full Text] [Related]
8. miR-19-3p Targets pten to Regulate cervical cancer Cell Proliferation, Invasion, and Autophagy.
Wang W; Liu L; Tian Y
Genet Res (Camb); 2023; 2023():4784500. PubMed ID: 36908850
[TBL] [Abstract] [Full Text] [Related]
9. Machine learning for genetic prediction of chemotherapy toxicity in cervical cancer.
Guo L; Wang W; Xie X; Wang S; Zhang Y
Biomed Pharmacother; 2023 May; 161():114518. PubMed ID: 36906972
[TBL] [Abstract] [Full Text] [Related]
10.
Flores Legarreta A; Salvo G; Gonzales NR; Chisholm G; Hillman RT; Frumovitz M
J Gynecol Oncol; 2023 Jul; 34(4):e50. PubMed ID: 36807750
[TBL] [Abstract] [Full Text] [Related]
11. ROS1 as a possible prognostic biomarker of cervical adenocarcinoma: An exploratory analysis with next-generation sequencing.
Machida H; Matsuo K; Tanaka M; Kitatani K; Takase A; Yokoyama K; Kajiwara H; Yasaka M; Ikeda M; Yoshida H; Hirasawa T; Mikami M
Gynecol Oncol; 2023 Apr; 171():59-66. PubMed ID: 36804622
[TBL] [Abstract] [Full Text] [Related]
12. Foxo3a-Mediated DNMT3B Impedes cervical cancer Cell Proliferation and Migration Capacities through Suppressing pten Promoter Methylation.
Li H; Yuan Y; Dong H; Wang T; Zhang D; Zhou L; Chen L; He X
J Invest Surg; 2023 Dec; 36(1):2162170. PubMed ID: 36653180
[TBL] [Abstract] [Full Text] [Related]
13. Machine learning-based models for genomic predicting neoadjuvant chemotherapeutic sensitivity in cervical cancer.
Guo L; Wang W; Xie X; Wang S; Zhang Y
Biomed Pharmacother; 2023 Mar; 159():114256. PubMed ID: 36652730
[TBL] [Abstract] [Full Text] [Related]
14. Senolytic Therapy: A Potential Approach for the Elimination of Oncogene-Induced Senescent HPV-Positive Cells.
Saleh T; Khasawneh AI; Himsawi N; Abu-Raideh J; Ejeilat V; Elshazly AM; Gewirtz DA
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555154
[TBL] [Abstract] [Full Text] [Related]
15. Targeting the PI3K Pathway in Gynecologic Malignancies.
Avila M; Grinsfelder MO; Pham M; Westin SN
Curr Oncol Rep; 2022 Dec; 24(12):1669-1676. PubMed ID: 36401704
[TBL] [Abstract] [Full Text] [Related]
16. LncRNA MEG3 promotes cisplatin sensitivity of cervical cancer cells by regulating the miR-21/pten axis.
Du Y; Geng G; Zhao C; Gao T; Wei B
BMC Cancer; 2022 Nov; 22(1):1145. PubMed ID: 36344947
[TBL] [Abstract] [Full Text] [Related]
17. Genomic landscape, immune characteristics and prognostic mutation signature of cervical cancer in China.
Liu J; Li Z; Lu T; Pan J; Li L; Song Y; Hu D; Zhuo Y; Chen Y; Xu Q
BMC Med Genomics; 2022 Nov; 15(1):231. PubMed ID: 36333792
[TBL] [Abstract] [Full Text] [Related]
18. An integrative approach toward identification and analysis of therapeutic targets involved in HPV pathogenesis with a focus on carcinomas.
Gupta AK; Kumar M
Cancer Biomark; 2023; 36(1):31-52. PubMed ID: 36245368
[TBL] [Abstract] [Full Text] [Related]
19. GFPT1 promotes the proliferation of cervical cancer via regulating the ubiquitination and degradation of pten.
Li D; Guan M; Cao X; Zha ZQ; Zhang P; Xiang H; Zhou Y; Peng Q; Xu Z; Lu L; Liu G
Carcinogenesis; 2022 Nov; 43(10):969-979. PubMed ID: 36040914
[TBL] [Abstract] [Full Text] [Related]
20. Small Cell and Other Rare Histologic Types of cervical cancer.
Marchocki Z; Swift B; Covens A
Curr Oncol Rep; 2022 Nov; 24(11):1531-1539. PubMed ID: 35947285
[TBL] [Abstract] [Full Text] [Related]
[Next]
